Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727045 | 0.89 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL20212163 | 0.88 | SIGMAR1 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL21660401 | 0.88 | CYP3A4 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL23703399 | 0.88 | CYP3A4 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL20212164 | 0.88 | SIGMAR1 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL21644743 | 0.87 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL21644742 | 0.87 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL3164205 | 0.86 | TACR1 (0.38) | CYP3A4 | |
| SCHEMBL5826953 | 0.84 | CYP3A4 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL16633342 | 0.84 | CYP3A4 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3319970-B1 | PYRIDO-OXAZINONE DERIVATIVES AS TNAP INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2019-08-28 | — | — | EP | disclosed |
| US-10221195-B2 | Pyridine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-03-05 | — | — | US | disclosed |
| US-20180141960-A1 | PYRIDINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-05-24 | — | — | US | disclosed |
| US-9920068-B2 | Pyridine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-03-20 | — | — | US | disclosed |
| US-9879032-B2 | Pyridine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-01-30 | — | — | US | disclosed |
| US-20170240562-A1 | PYRIDINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-24 | — | — | US | disclosed |
| US-20170210755-A1 | PYRIDINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141960-A1 | PYRIDINE COMPOUNDS | ALPI, ALPP, ALPL | CYP3A4 403/4885HTT 4830/4885SMN1; SMN2 4087/4885 |
| US-20170240562-A1 | PYRIDINE COMPOUNDS | ALPI, ALPP, ALPL | CYP3A4 403/4885HTT 4830/4885SMN1; SMN2 4087/4885 |
| US-10221195-B2 | Pyridine compounds | ALPI, ALPP, ALPL | CYP3A4 403/4885HTT 4830/4885SMN1; SMN2 4087/4885 |
| US-20170210755-A1 | PYRIDINE COMPOUNDS | ALPI, ALPP, ALPL | CYP3A4 403/4885HTT 4830/4885SMN1; SMN2 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.